ImmuneOnco announces the appointment of Dr. Kathy Yu as Vice President of the Company
On March 30, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced the appointment of Dr. Kathy Yu as Vice President of the Company, with overall responsibility for the Company's BD affairs.
Dr.Yu Xiaoxu graduated from the Department of Clinical Medicine at Concord Medical Dr. Kathy Yu graduated from the Department of Clinical Medicine at Peking Union Medical College and holds a MBA degree from Rutgers University in the United States. She has 25 years of experience in the biopharmaceutical industry and worked at Novartis, Smith, Kline & French, UCB China, Pfizer, Merck and Corning Jerry's, where she held various positions in medicine, marketing, business development and strategic planning. Dr. Yu has cross-cultural experiences in China, Europe and North America. For 15 years, she has led business development at UCB China, Pfizer and Merck Pharmaceuticals Co., Ltd. in licensing of various important products, joint development and commercialization, as well as establishing international joint ventures and post-acquisition integrations.
ImmuneOnco Biopharmaceutical Technology (Shanghai) Co., Ltd. was founded in June 2015 and is registered as Zhangjiang Hi-Tech Park in Shanghai. The company is mainly committed to cancer immunotherapy product development, including bi-specific antibodies, new recombinant fusion proteins, as well as TANKTM cellular therapy. A common feature of these products is to activate the patient's own immune system to play anti-tumor effects, and ultimately inhibit the endless growth of tumor cells, reversing malignant symptoms, so that patients gradually return to healthy.
For further cooperation, please contact
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573